Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024
Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Genetic pleiotropy differentially linking brain variation to cannabis use and cannabis use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Adverse outcomes following psychedelic use in adolescents and adults: associations with age and personality traits.Child and adolescent psychiatry and mental health · 2026Article
- Multisystem regulation of reward and addiction: beyond the dopaminergic system.Frontiers in pharmacology · 2026Review
- Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The Endocannabinoid System in Human Disease: Molecular Signaling, Receptor Pharmacology, and Therapeutic Innovation.International journal of molecular sciences · 2025Review
- Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co-Use: Results From the European Web Survey on Drugs.Drug and alcohol review · 2025Article
- Cannabinoid CB1 receptor-sensitive neurodevelopmental processes and trajectories.Molecular psychiatry · 2025Review
- An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.Pharmaceutics · 2025Review
- Oral cannabidiol did not impair learning and memory in healthy adults.Journal of cannabis research · 2025Article
- Give me five! A modern perspective on addiction from the up-dated Freudian drive theory.Frontiers in psychiatry · 2025Article
- The endocannabinoid system in the brain undergoes long-lasting changes following neuropathic pain.iScience · 2024Review
- Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials.Child and adolescent psychiatry and mental health · 2024Review
- Associations between mesolimbic connectivity, and alcohol use from adolescence to adulthood.Developmental cognitive neuroscience · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Adolescence is a time of rapid neurodevelopment and the endocannabinoid system is particularly prone to change during this time. Cannabis is a commonly used drug with a particularly high prevalence of use among adolescents. The two predominant phytocannabinoids are Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which affect the endocannabinoid system. It is unknown whether this period of rapid development makes adolescents more or less vulnerable to the effects of cannabis on brain-network connectivity, and whether CBD may attenuate the effects of THC. Using fMRI, we explored the impact of vaporized cannabis (placebo, THC: 8 mg/75 kg, THC + CBD: 8 mg/75 kg THC & 24 mg/75 kg CBD) on resting-state networks in groups of semi-regular cannabis users (usage frequency between 0.5 and 3 days/week), consisting of 22 adolescents (16-17 years) and 24 young adults (26-29 years) matched for cannabis use frequency. Cannabis caused reductions in within-network connectivity in the default mode (F[2,88] = 3.97, P = 0.022, η² = 0.018), executive control (F[2,88] = 18.62, P < 0.001, η² = 0.123), salience (F[2,88] = 12.12, P < 0.001, η² = 0.076), hippocampal (F[2,88] = 14.65, P < 0.001, η² = 0.087), and limbic striatal (F[2,88] = 16.19, P < 0.001, η² = 0.102) networks compared to placebo. Whole-brain analysis showed cannabis significantly disrupted functional connectivity with cortical regions and the executive control, salience, hippocampal, and limbic striatal networks compared to placebo. CBD did not counteract THC's effects and further reduced connectivity both within networks and the whole brain. While age-related differences were observed, there were no interactions between age group and cannabis treatment in any brain network. Overall, these results challenge the assumption that CBD can make cannabis safer, as CBD did not attenuate THC effects (and in some cases potentiated them); furthermore, they show that cannabis causes similar disruption to resting-state connectivity in the adolescent and adult brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.